Skip to main navigation

Pulse: medical technology report 2011 - Financial performance - EY - Global

Pulse: medical technology report 2011

Financial performance

  • Share
Growth within each of 2010's major financial indicators outpaced 2009's growth rates.

Publicly traded medtech companies in the US and Europe turned in a solid performance in 2010.

Financial outlook for medtech

Revenue growth was led in large part by conglomerates that rebounded after declining in 2009.

Growth within each of 2010's major financial indicators outpaced 2009's growth rates.

Medical technology at a glance, 2010
(US$b, data for non-conglomerates except where indicated)


Public company data 2010 2009 % change
Revenues $315.9 $303.6 4%
    Conglomerates $122.3 $116.5 5%
    Non-conglomerates $193.7 $187.1 4%
R&D expense $12.4 $11.61 7%
Net income $17.4 $12.2 43%
Cash and cash equivalents
and short-term investments
$42.0 $35.8 17%
Number of employees 764,355 739,531 3%
Number of public companies 436 443 -2%

Source: EY and Capital IQ
Data shown for US and European public companies.

Looking ahead, the industry continues to grapple with mounting pressures and faces considerable uncertainty due to global economic events.

Yet, several factors may positively effect medtech's long term growth.

  • Further expansion into emerging and underserved markets
  • Aging Western populations
  • Longer life expectancies
  • A gradual improvement in the global economy

However, to sustain growth in the immediate future, companies will need to address the pressures listed above.



<< Previous | Next >>

Contents

Related content

Download


Contact us

    To learn more about how we can help your medical technology strategy, contact:

  • John Babitt
    +1 212 773 0912
Back to top